Cryo-Cell

CCELPhase 2

Cryo-Cell International is a pioneer and established commercial leader in the family cord blood banking industry, founded in 1989. The company's core business is the cryopreservation and storage of hematopoietic stem cells derived from umbilical cord blood, offering families a form of biological insurance. While its primary revenue is generated from storage services, Cryo-Cell also engages in research and development related to cellular therapies. The company faces a competitive landscape but maintains a strong brand and a large existing client base.

Market Cap

$4.5M

Employees

50-200

Focus

Biotech

CCEL · Stock Price

USD 0.709.86 (-93.37%)

Historical price data

AI Company Overview

Technology Platform

Proprietary, automated closed-system technology for processing and cryopreserving umbilical cord blood stem cells and cord tissue for long-term storage.

Pipeline Snapshot

1 drug in pipeline

Drug	Indication	Stage
Cord Tissue Mesenchymal Stromal Cells	Autism	Phase 2

Opportunities

Growth opportunities include expanding market share in a competitive private banking sector, geographic expansion, and potential increased demand if research validates new therapeutic uses for banked cord tissue-derived mesenchymal stem cells in regenerative medicine.

Risk Factors

Key risks include intense price competition, regulatory changes, reliance on recurring storage fee revenue, potential stagnation if therapeutic applications for banked cells do not expand, and vulnerability to economic downturns affecting discretionary spending.

Competitive Landscape

Main competitors are other large private cord blood banks like CBR Systems, ViaCord, and Americord. Cryo-Cell differentiates through its long operating history (since 1989), public company transparency, AABB accreditation, and proprietary processing technology.